title: Do RARA/PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia?
authors.forename: S
authors.initials: S
authors.lastname: Subramaniyam
authors.forename: S V
authors.initials: SV
authors.lastname: Nandula
authors.forename: G
authors.initials: G
authors.lastname: Nichols
authors.forename: M
authors.initials: M
authors.lastname: Weiner
authors.forename: P
authors.initials: P
authors.lastname: Satwani
authors.forename: B
authors.initials: B
authors.lastname: Alobeid
authors.forename: G
authors.initials: G
authors.lastname: Bhagat
authors.forename: V V
authors.initials: VV
authors.lastname: Murty
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D017353:Gene Deletion; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin